Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
Mark HJ Wessels, Charlotte E. Teunissen(Amsterdam Neuroscience), Eva Strijbis(Amsterdam University Medical Centers), Samantha Noteboom(Université de Bordeaux), Zoé L. E. van Kempen(Amsterdam Neuroscience), Zoë YGJ van Lierop(Amsterdam Neuroscience), Bernard M.J. Uitdehaag(Amsterdam UMC Location Vrije Universiteit Amsterdam), Frederik Barkhof(Netherlands Institute for Neuroscience), Menno M. Schoonheim(Amsterdam Neuroscience), Joep Killestein(Amsterdam UMC Location Vrije Universiteit Amsterdam), Bastiaan Moraal(Amsterdam UMC Location Vrije Universiteit Amsterdam), Johannes A. Heijst(Amsterdam Neuroscience)
Cited by 17
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
|Multiple Sclerosis Journal|2020|2.5k